Clinical trial
Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic…
NCT00217386 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00217386 |
|---|---|
| Title | Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes |
| Official title | Therapy of Early Stage Myelodysplastic Syndrome (MDS) With ATG and Etanercept |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases |
| Intervention type | Biological |
| Interventions | anti-thymocyte globulin, etanercept |
| Enrollment | 30 |
| Start date | Mar 1, 2004 |
| Primary completion | Dec 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 15, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: